Jasper Therapeutics Inc (JSPR) - Net Assets
Based on the latest financial reports, Jasper Therapeutics Inc (JSPR) has net assets worth $11.57 Million USD as of September 2025. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets ($57.47 Million) and total liabilities ($45.90 Million). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Check Jasper Therapeutics Inc (JSPR) asset resilience to evaluate the company's liquid asset resilience ratio.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | $11.57 Million |
| % of Total Assets | 20.13% |
| Annual Growth Rate | 23.91% |
| 5-Year Change | N/A |
| 10-Year Change | N/A |
| Growth Volatility | 137.67 |
Jasper Therapeutics Inc - Net Assets Trend (2019–2024)
This chart illustrates how Jasper Therapeutics Inc's net assets have evolved over time, based on quarterly financial data. Also explore JSPR current and non-current assets for the complete picture of this company's asset base.
Annual Net Assets for Jasper Therapeutics Inc (2019–2024)
The table below shows the annual net assets of Jasper Therapeutics Inc from 2019 to 2024. For live valuation and market cap data, see JSPR company net worth.
| Year | Net Assets | Change |
|---|---|---|
| 2024-12-31 | $61.67 Million | -21.37% |
| 2023-12-31 | $78.44 Million | +117.96% |
| 2022-12-31 | $35.99 Million | -48.23% |
| 2021-12-31 | $69.52 Million | +297.89% |
| 2020-12-31 | $-35.13 Million | -266.48% |
| 2019-12-31 | $21.10 Million | -- |
Equity Component Analysis
This analysis shows how different components contribute to Jasper Therapeutics Inc's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 23572500000.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (December 2024)
| Component | Amount | Percentage |
|---|---|---|
| Common Stock | $2.00K | 0.00% |
| Other Components | $302.54 Million | 490.55% |
| Total Equity | $61.67 Million | 100.00% |
Jasper Therapeutics Inc Competitors by Market Cap
The table below lists competitors of Jasper Therapeutics Inc ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
A SPAC III Acquisition Corp. Class A Ordinary Shares
NASDAQ:ASPC
|
$26.04 Million |
|
Origin Materials Inc
NASDAQ:ORGN
|
$26.06 Million |
|
Getin Holding SA
WAR:GTN
|
$26.06 Million |
|
Venteny Fortuna International
JK:VTNY
|
$26.07 Million |
|
Avante Logixx Inc
V:XX
|
$26.02 Million |
|
Shanghai Shenqi Pharmaceutical Investment Management Co Ltd B
SHG:900904
|
$26.01 Million |
|
Hitech Corporation Limited
NSE:HITECHCORP
|
$26.00 Million |
|
Bayfirst Financial Corp
NASDAQ:BAFN
|
$25.98 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Jasper Therapeutics Inc's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2023 to 2024, total equity changed from 78,440,000 to 61,674,000, a change of -16,766,000 (-21.4%).
- Net loss of 71,269,000 reduced equity.
- Share repurchases of 360,000 reduced equity.
- New share issuances of 47,195,000 increased equity.
- Other factors increased equity by 7,668,000.
Equity Change Factors (2023 to 2024)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | $-71.27 Million | -115.56% |
| Share Repurchases | $360.00K | -0.58% |
| Share Issuances | $47.20 Million | +76.52% |
| Other Changes | $7.67 Million | +12.43% |
| Total Change | $- | -21.37% |
Book Value vs Market Value Analysis
This analysis compares Jasper Therapeutics Inc's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 0.22x
- The company is trading below its book value, potentially indicating the market believes the assets are overvalued on the balance sheet or anticipates future losses.
- The price-to-book ratio has increased from 0.01x to 0.22x over the analyzed period, suggesting growing market confidence.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2019-12-31 | $119.90 | $0.93 | x |
| 2020-12-31 | $-203.08 | $0.93 | x |
| 2021-12-31 | $61.01 | $0.93 | x |
| 2022-12-31 | $9.87 | $0.93 | x |
| 2023-12-31 | $7.51 | $0.93 | x |
| 2024-12-31 | $4.23 | $0.93 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Jasper Therapeutics Inc utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): -115.56%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: 0.00%
- • Asset Turnover: 0.00x
- • Equity Multiplier: 1.30x
- Recent ROE (-115.56%) is below the historical average (-61.69%), suggesting potential challenges in capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2019 | -23.63% | 0.00% | 0.00x | 1.29x | $-7.10 Million |
| 2020 | 0.00% | 0.00% | 0.00x | 0.00x | $-28.16 Million |
| 2021 | -44.07% | -494.46% | 0.07x | 1.35x | $-37.59 Million |
| 2022 | -104.71% | -278.92% | 0.28x | 1.34x | $-41.28 Million |
| 2023 | -82.18% | 0.00% | 0.00x | 1.21x | $-72.31 Million |
| 2024 | -115.56% | 0.00% | 0.00x | 1.30x | $-77.44 Million |
Industry Comparison
This section compares Jasper Therapeutics Inc's net assets metrics with peer companies in the Biotechnology industry.
Industry Context
- Industry: Biotechnology
- Average net assets among peers: $44,828,400
- Average return on equity (ROE) among peers: -124.18%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Jasper Therapeutics Inc (JSPR) | $11.57 Million | -23.63% | 3.97x | $26.03 Million |
| Aardvark Therapeutics, Inc. Common Stock (AARD) | $-54.64 Million | 0.00% | 0.00x | $118.88 Million |
| Abcellera Biologics Inc (ABCL) | $10.25 Million | -21.57% | 1.29x | $1.07 Billion |
| Abeona Therapeutics Inc (ABEO) | $3.60 Million | -91.89% | 0.28x | $292.09 Million |
| Acumen Pharmaceuticals Inc (ABOS) | $266.97 Million | -19.62% | 0.16x | $171.87 Million |
| Abpro Holdings, Inc. (ABP) | $3.07 Million | -479.81% | 1.57x | $448.19K |
| Absci Corp (ABSI) | $67.00 Million | -21.42% | 0.32x | $345.85 Million |
| Arbutus Biopharma Corp (ABUS) | $88.00 Million | -44.09% | 0.34x | $840.56 Million |
| ABVC Biopharma Inc (ABVC) | $80.00K | -31.70% | 0.38x | $26.41 Million |
| Abivax SA American Depositary Shares (ABVX) | $40.58 Million | -434.26% | 4.06x | $9.33 Billion |
| ACADIA Pharmaceuticals Inc (ACAD) | $23.36 Million | -97.44% | 0.37x | $3.74 Billion |
About Jasper Therapeutics Inc
Jasper Therapeutics, Inc., a clinical-stage biotechnology company, focuses on developing therapeutics targeting mast and hematopoietic stem cell driven diseases. The company's lead product candidate is briquilimab, a monoclonal antibody designed to block stem cell factor from binding to and signaling through the CD117 receptor on mast and stem cells. It focuses on the development and commercializ… Read more